A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Journal: Annals of the Rheumatic Diseases
Year: 2017

NCT01645280.